Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK).
Kirk E HevenerBernard D SantarsieroHyun LeeJesse A JonesTeuta BociMichael E JohnsonShahila MehboobPublished in: Acta crystallographica. Section F, Structural biology communications (2018)
Enoyl-acyl carrier protein (ACP) reductase II (FabK) is a critical rate-limiting enzyme in the bacterial type II fatty-acid synthesis (FAS II) pathway. FAS II pathway enzymes are markedly disparate from their mammalian analogs in the FAS I pathway in both structure and mechanism. Enzymes involved in bacterial fatty-acid synthesis represent viable drug targets for Gram-negative pathogens, and historical precedent exists for targeting them in the treatment of diseases of the oral cavity. The Gram-negative organism Porphyromonas gingivalis represents a key causative agent of the costly and highly prevalent disease known as chronic periodontitis, and exclusively expresses FabK as its enoyl reductase enzyme in the FAS-II pathway. Together, these characteristics distinguish P. gingivalis FabK (PgFabK) as an attractive and novel narrow-spectrum antibacterial target candidate. PgFabK is a flavoenzyme that is dependent on FMN and NADPH as cofactors for the enzymatic reaction, which reduces the enoyl substrate via a ping-pong mechanism. Here, the structure of the PgFabK enzyme as determined using X-ray crystallography is reported to 1.9 Å resolution with endogenous FMN fully resolved and the NADPH cofactor partially resolved. PgFabK possesses a TIM-barrel motif, and all flexible loops are visible. The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity. The PgFabK structure and the insights gleaned from its analysis will facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.
Keyphrases
- gram negative
- multidrug resistant
- fatty acid
- drug discovery
- reactive oxygen species
- emergency department
- magnetic resonance imaging
- high resolution
- combination therapy
- computed tomography
- magnetic resonance
- drug delivery
- molecular docking
- replacement therapy
- nitric oxide
- single molecule
- antimicrobial resistance
- smoking cessation
- case control
- adverse drug
- anti inflammatory